You are here

Article Text

Article menu
Download PDFPDF
Letters
Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype
  1. Pedro Machado1,2,
  2. Robert Landewé3,4,
  3. Jürgen Braun5,
  4. Xenofon Baraliakos5,
  5. Kay-Geert A Hermann6,
  6. Benjamin Hsu7,
  7. Daniel Baker7,
  8. Désirée van der Heijde1
  1. 1 Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
  2. 2 Department of Rheumatology, Coimbra University Hospital, Coimbra, Portugal
  3. 3 Department of Clinical Immunology & Rheumatology, Academic Medical Center, Amsterdam, The Netherlands
  4. 4 Department of Rheumatology, Atrium Medical Center, Heerlen, The Netherlands
  5. 5 Department of Rheumatology, RheumazentrumRuhrgebiet, Herne, Germany
  6. 6 Department of Radiology, Charité Medical School, Berlin, Germany
  7. 7 Department of Research and Development, Centocor Inc., Malvern, Pennsylvania, USA
  1. Correspondence to Professor Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, Leiden 2300 RC, The Netherlands; mail{at}dvanderheijde.nl

https://doi.org/10.1136/annrheumdis-2012-202922

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Psoriasis is an important clinical feature in ankylosing spondylitis (AS) and spondyloarthritis (SpA) in general,1 with inflammatory spinal disease developing in 5%–25% of psoriasis cases.2 ,3 However, there have been few studies assessing the differences between AS patients with and without concomitant psoriasis.4–9

    Our aim was to compare the demographic, clinical and imaging characteristics between AS patients with and without psoriasis. Baseline data from an 80% random sample of the AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) database were used for this analysis. Details of the ASSERT trial and study population have been previously published.10 Briefly, patients with active AS (fulfilling modified New York criteria) for at least 3 months, a Bath AS disease activity index score of at least 4 (range 0–10) and a spinal pain assessment score of at least 4 (range 0–10) were eligible for the study.

    AS patients with …

    View Full Text

    Footnotes

    • Contributors All authors participated in the design of the analyses. PM, RL and DvdH performed the analyses. All authors participated in drafting the paper and all authors approved the final manuscript.

    • Funding PM was supported by the Fundação para a Ciência e a Tecnologia (FCT) grant SFRH/BD/62329/2009.

    • Competing interests None.

    • Ethics approval Ethics committee approval was secured for the ASSERT trial. This study is an investigator-preformed subanalysis of the ASSERT cohort.

    • Provenance and peer review Not commissioned; externally peer reviewed.